Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients  by Huang, Cindy X. et al.
Both low muscle mass and low fat are associated with
higher all-cause mortality in hemodialysis patients
Cindy X. Huang1, Hocine Tighiouart1, Srinivasan Beddhu2, Alfred K. Cheung2, Johanna T. Dwyer1,
Garabed Eknoyan3, Gerald J. Beck4, Andrew S. Levey1 and Mark J. Sarnak1
1Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA; 2Department of Medicine,
University of Utah, Salt Lake City, Utah, USA; 3Department of Medicine, Baylor College of Medicine, Houston, Texas, USA and
4Department of Biostatistics and Epidemiology, Cleveland Clinic, Cleveland, Ohio, USA
A higher body mass index is associated with better outcomes
in hemodialysis patients; however, this index does not
differentiate between fat and muscle mass. In order to clarify
this, we examined the relationship between measures of fat
and muscle mass and mortality in 1709 patients from the
Hemodialysis Study. Triceps skin-fold thickness was used to
assess body fat and mid-arm muscle circumference was used
to assess muscle mass. Cox regression was used to evaluate
the relationship between measures of body composition
with all-cause mortality after adjustments for demographic,
cardiovascular, dialysis, and nutrition-related risk factors.
During a median follow-up of 2.5 years, there were 802
deaths. In adjusted models with continuous covariates,
higher triceps skin-fold thickness and higher body mass
index were significantly associated with decreased hazards of
mortality, while higher mid-arm muscle circumference
showed a trend toward decreased mortality. In adjusted
models, lower quartiles of triceps skin-fold thickness,
mid-arm muscle circumference, and body mass index were all
significantly associated with higher all-cause mortality. These
studies show that body composition in end-stage renal
disease bears a complex relationship to all-cause mortality.
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Although obesity is associated with higher mortality in the
general population,1 studies of dialysis patients suggest that
higher body mass index (BMI) may be associated with lower
all-cause and cardiovascular mortality.2–6 The reason for this
difference is unknown, but one potential explanation is that
BMI does not differentiate between fat and muscle mass.
Higher fat mass is associated with inflammation and
adverse outcomes in the general population,7 although there
are fewer and inconsistent data regarding this relationship in
patients with end-stage renal disease.8,9 Higher muscle mass
on the other hand may be protective in dialysis patients
because it is a proxy for better nutritional status. Most of the
previous studies examining the importance of obesity in
dialysis patients have however used BMI as a measure of
obesity, therefore the interpretation remain uncertain.
The purpose of this study was to evaluate the separate
associations of fat and muscle mass with all-cause mortality
in hemodialysis (HD) patients. We also evaluated whether fat
and muscle mass confounded or modified the association of
one another and compared their associations with BMI.
RESULTS
Baseline characteristics
The demographics and other clinical characteristics of patients
at baseline are shown in Table 1. The average age was 58 years,
64% were African Americans, and more than half were
females. The most common cause of end-stage renal disease
was diabetes (38%), followed by hypertension (34%) and
glomerular disease (14%). Forty percent of patients had a
history of congestive heart failure (HF) 39% had ischemic
heart disease, and 44% had diabetes. Mean triceps skin-fold
thickness, mid-arm muscle circumference (MAMC), and BMI
were 16.3 mm, 24.8 cm, and 25.2 kg/m2, respectively.
Participants in the highest quartile of triceps skin-fold
thickness were older, predominantly women, more likely to
be African American, with shorter dialysis vintage, higher
prevalence of diabetes and co-morbid conditions, as well as
higher BMI, higher MAMC, and lower serum creatinine
levels (Table 1).
The Pearson correlation coefficients were 0.62, 0.63, and
0.17 between triceps skin-fold thickness and BMI, MAMC
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and BMI, and triceps skin-fold thickness and MAMC,
respectively. MAMC was normally distributed, while triceps
skin-fold thickness and BMI were slightly skewed to the right
(Figure 1). During a median follow-up of 2.5 years there were
802 deaths.
Univariate analyses
In univariate analysis, higher measures of all three parameters
of body composition measures were associated with lower all-
cause mortality (hazards ratio (HR) 0.93 (95% confidence
interval (CI) 0.86–1.00, P¼ 0.04), 0.87 (95% CI 0.81–0.94,
Po0.001), and 0.92 (95% CI 0.85–0.99, P¼ 0.02), respec-
tively, for triceps skin-fold thickness, MAMC, and BMI).
For triceps skin-fold thickness and BMI, the highest quartile
was associated with lower risk compared with the lowest
Table 1 | Patient characteristics by quartile of triceps skin-fold thickness
Overall
(n=1709)
Triceps skin-fold
thickness Q1 (n=427)
Triceps skin-fold
thickness Q2 (n=430)
Triceps skin-fold
thickness Q3 (n=422)
Triceps skin-fold
thickness Q4 (n=430) P
Demographics
Age (years) 57.7 (14.0) 54.4 (15.7) 59.1 (14.2) 58.2 (13.6) 59.2 (11.5) o0.001
Women 56 26 45 71 80 o0.001
Black 64 60 60 68 69 0.002
Comorbid conditions
Diabetes 44 22 41 53 60 o0.001
Peripheral vascular
disease
16 14 16 17 18 0.36
Ischemic heart
disease
39 33 43 39 41 0.01
Congestive heart
failure
40 42 40 37 40 0.44
Other heart disease 63 66 65 62 59 0.12
Cerebral vascular
disease
20 17 23 22 17 0.06
Smoking status
Never 49 38 49 52 58 o0.001
Past 33 36 31 33 32
Current 18 26 20 15 10
Physical exam
Height (cm) 164.8 (9.4) 167.9 (9.5) 165.5 (9.3) 163.4 (9.4) 162.4 (8.3) o0.001
Weight (kg) 68.8 (14.4) 61.3 (11.0) 65.9 (12.4) 69.9 (13.8) 78.1 (14.4) o0.001
Triceps skin-fold
thickness (mm)
16.3 (7.9) 7.1 (1.8) 12.6 (1.5) 18.2 (1.8) 27.4 (4.2)
MAMC (cm) 24.8 (3.8) 24.1 (3.9) 24.4 (3.6) 25.0 (3.8) 25.7 (3.9) o0.001
BMI (kg/m2) 25.2 (5.1) 21.5 (3.0) 23.9 (3.5) 26.0 (4.4) 29.6 (5.1) o0.001
SBP (mmHg) 152.1 (22.1) 150.2 (20.9) 150.1 (22.3) 152.4 (22.5) 155.5 (22.2) 0.001
Laboratory variables
Creatinine (mg/dl) 10.3 (2.9) 10.9 (3.3) 10.3 (2.9) 10.1 (2.7) 9.9 (2.5) o0.001
Albumin (g/dl) 3.6 (0.4) 3.7 (0.4) 3.6 (0.4) 3.6 (0.3) 3.6 (0.3) 0.86
Calcium (mg/dl) 9.3 (1.0) 9.3 (1.0) 9.3 (1.0) 9.3 (1.0) 9.2 (0.9) 0.47
Phosphorous (mg/dl) 5.8 (1.9) 5.8 (2.1) 5.6 (1.8) 5.8 (1.9) 5.9 (1.6) 0.18
Dialysis-related parameters
Duration of HD
(years)
3.7 (4.4) 4.8 (5.3) 3.8 (4.3) 3.5 (4.0) 2.8 (3.4) o0.001
Abbreviations: BMI, body mass index; HD, hemodialysis; MAMC, mid-arm muscle circumference; SBP, systolic blood pressure.
Data are presented as mean (s.d.) for continuous variables, or as percentages for binary and categorical variables. The P-values are derived from two-sided hypothesis testing
using w2-test for categorical variables and analysis of variance for continuous variables.
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Figure 1 |Histogram of anthropometric measures.
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quartile, while for MAMC the three highest quartiles were
associated with lower risk compared with the lowest quartile
(Table 2).
Functional form of anthropometric measures
Adjusted restricted cubic spline analysis suggested a linear
relationship between all-cause mortality and triceps skin-fold
thickness (Figure 2). For MAMC the relationship was not
linear, with mortality highest in the lowest quartile and
reaching a plateau at 25 cm. The quadratic term for MAMC
was not significant (P¼ 0.14). For BMI the relationship was
U-shaped (P¼ 0.001 for quadratic term), with the lowest risk
at 30 kg/m2 (Figure 2).
Multivariate analyses
The negative association between triceps skin-fold thickness
and all-cause mortality became stronger after adjusting for
demographics, comorbid conditions, nutritional status, lab-
oratory test, and dialysis characteristics. For example, after
adjustment for diabetes, the HR for triceps skin-fold
thickness for the second, third, and fourth quartile in
comparison with the first quartile changed from 0.92, 0.95,
and 0.77 to 0.81, 0.77, and 0.60 respectively. The HR further
decreased slightly after adjustment for other covariates
as mentioned above, including demographics, comorbid
conditions, systolic blood pressure, and smoking (Table 2).
Higher triceps skin-fold thickness and BMI were significantly
associated with lower all-cause mortality in continuous
analysis, while MAMC was marginally significant. The HRs
per 1 s.d. increase were 0.84 (95% CI 0.76–0.92), 0.93
(95% CI 0.86–1.00), and 0.88 (95% CI 0.81-0.96) for
triceps skin-fold thickness, MAMC, and BMI, respectively.
The three highest quartiles of triceps skin-fold thickness,
MAMC, and BMI were all significantly associated with lower
all-cause mortality in comparison with the lowest quartile
(Table 2). There was no significant interaction between
triceps skin-fold thickness and MAMC (P¼ 0.45), sex and
triceps skin-fold thickness (P¼ 0.49), and sex and MAMC
(P¼ 0.17). There were also no significant interactions
(P40.05) between any of the body composition measures
with either diabetes, ischemic heart disease, HF, other heart
disease, or smoking.
Sensitivity analyses
Higher triceps skin-fold thickness and MAMC were
associated with lower mortality when both variables
were included in the same model and the HRs of each did
Table 2 | Associations between anthropometric measurements and all-cause mortality in HD patients
Unadjusted model Adjusted modela Additional adjustmentb
Mortality n (%) HR 95% CI HR 95% CI HR 95% CI
Triceps skin-fold thickness quartiles Pc=0.02 Pco0.001 Adjusted for MAMC, Pco0.001
Q1 (1.7–10.1mm) 212 (49.6) Reference Reference Reference
Q2 (1.0.2–15.3mm) 213 (49.5) 0.92 0.76–1.12 0.68 0.56–0.84 0.70 0.57–0.86
Q3 (15.4–21.6mm) 207 (49.1) 0.95 0.78–1.15 0.70 0.56–0.88 0.75 0.60–0.94
Q4 (21.7–44.5mm) 170 (39.5) 0.77 0.63–0.95 0.55 0.43–0.70 0.59 0.46–0.76
MAMC quartiles Pco0.001 Pc=0.003 Adjusted for triceps skin-fold thickness, Pc=0.07
Q1 (9.0–22.3 cm) 240 (56.2) Reference Reference Reference
Q2 (22.4–24.5 cm) 202 (47.3) 0.73 0.60–0.88 0.68 0.55–0.83 0.71 0.58–0.87
Q3 (24.6–27.0 cm) 181 (42.3) 0.64 0.52–0.78 0.70 0.56–0.87 0.76 0.61–0.95
Q4 (27.0–43.9 cm) 179 (41.9) 0.61 0.50–0.75 0.69 0.55–0.86 0.77 0.62–0.97
BMI quartiles Pc=0.02 Pc=0.002
Q1 (15.5–21.6 kg/m2) 222 (52.1) Reference Reference — —
Q2 (21.6–24.4 kg/m2) 206 (47.9) 0.90 0.74–1.09 0.79 0.65–0.96 — —
Q3 (24.5–28.1 kg/m2) 193 (45.2) 0.90 0.74–1.10 0.80 0.65–0.99 — —
Q4 (28.2–52.0 kg/m2) 181 (42.5) 0.77 0.64–0.95 0.64 0.52–0.80 — —
Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio; MAMC, mid-arm muscle circumference.
aAdjusted for age, sex, race, duration of dialysis, baseline creatinine, albumin, dialysis treatment group, diabetes, peripheral vascular disease, ischemic heart disease,
congestive heart failure, other heart disease, smoking, systolic blood pressure (linear and quadratic), and interaction between albumin and follow-up time.
bAdjusted for the above variables as well as MAMC in the triceps skin-fold thickness model, and for triceps skin-fold thickness in the MAMC model and triceps skin-fold
thickness.
cP-values are test for trend.
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Figure 2 |Adjusted restricted cubic splines of body
composition variables with all-cause mortality.
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not change appreciably (Table 2). Additional adjustment for
height in the MAMC or triceps skin-fold thickness model did
not significantly change the results (data not shown). When
creatinine was removed from the models the HRs for MAMC
and BMI were slightly stronger. For example, in adjusted
continuous analysis the HRs per 1 s.d. increase were 0.83
(95% CI 0.75–0.91), 0.90 (95% CI 0.83–0.97), and 0.85 (95%
CI 0.78–0.93) for triceps skin-fold thickness, MAMC, and
BMI, respectively. Finally in adjusted continuous models that
excluded patients who died in the first year (n¼ 204), the
HRs per 1 s.d. increase were similar to those in the initial
models: 0.87 (95% CI 0.78–0.97), 0.94 (95% CI 0.86–1.03),
and 0.90 (95% CI 0.82–0.99) for triceps skin-fold thickness,
MAMC, and BMI, respectively.
DISCUSSION
This study demonstrates that low muscle mass and low fat
mass are each associated with higher all-cause mortality in
HD patients. Although the relationship between triceps skin-
fold thickness and mortality was linear, the risk associated
with MAMC was particularly evident in the lowest quartile
(Table 2). There was no significant interaction between
triceps skin-fold thickness and muscle mass using either the
quartiles or the continuous forms of the covariates. In
addition, our results confirm the results of prior studies
demonstrating that lower BMI is associated with higher all-
cause mortality.
In our study, lower muscle mass is associated with worse
survival, and confirm the results of prior studies, which have
demonstrated the adverse prognostic significance of low
muscle mass.10 Data from a French study of 1345 HD
patients demonstrated that patients with the same BMI were
not equally protected from death; only patients with
BMI425 kg/m2 and serum creatinine (as a proxy for muscle
mass) 4800 mmol/l (9.0 mg/dl) had lower mortality, whereas
patients with serum creatinine o800 mmol/l and
BMI425 kg/m2 had higher annual mortality.11 Beddhu
et al.12 demonstrated that the protective effect of high BMI
was limited only to individuals with normal or high muscle
mass using urine creatinine as a proxy of muscle mass in
70,028 Medicare HD patients. The drawback of these three
studies is the indirect assessment of muscle mass from
creatinine measurements, in contrast to its direct assessment
in this report.
There are several reasons why low muscle mass may be
associated with worse survival. First, lower muscle mass may
reflect poor nutritional status.10 Second, low muscle mass
may reflect a level of inflammation.13 Honda et al. demon-
strated a significant increase of inflammation (CRPX10 mg/l)
in HD patients with low lean-body mass determined by
DEXA. Third, muscle mass may be the compartment in
which uremic toxins are distributed in HD patients. Gotch14
demonstrated that total body water and muscle mass are
strongly correlated and muscle mass is the primary location
of intracellular water. Therefore, patients with lower muscle
mass may have a higher concentration of uremic toxins.
Our results also show that lower fat mass is associated
with increased all-cause mortality, with the relationship being
linear in adjusted analysis (Figure 2). These results are
consistent with the finding of Kalantar-Zadeh et al.9 who
evaluated body fat by near infrared and noted that low
baseline body fat percentage and fat loss over time were
independently associated with higher mortality in HD
patients.
There are several reasons why lower fat mass may be
associated with higher mortality in dialysis patients. First,
lower fat mass may reflect the severity of underlying disease
that we unable to adjust for despite multivariable analyses.
Second, lower fat mass may reflect decreased energy stores for
coping with catabolic stress of dialysis.9 Third, although body
fat is associated with recruitment of macrophages and
inflammation in the general population,15 this is not as clear
in dialysis patients. In fact, no difference in inflammatory
markers (interleukin-6, tumor necrosis factor-a, C-reactive
protein) was noted in different body fat groups in several
studies;9,13,16 however other studies have noted higher levels
of inflammatory markers such as inflammatory high density
lipoprotein cholesterol (HDL) in those with higher BMI.17,18
It remains to be determined whether the association between
fat mass and inflammation is altered in the uremic state.
Our study confirms the previous finding of lower BMI
being associated with mortality,3,4,6,19 but also suggest a
‘U’-shaped relationship (Figure 2). The protective effect of
BMI seems to be maximal at BMI of 30 kg/m2, with increased
risk particularly below, but also above, this threshold. These
results are similar to those from the Dialysis Outcomes and
Practice Patterns Study where a ‘J’-shaped curve was reported,
with a BMI of 30–34.9 being most protective.6 These
observations suggest that a BMI target of o25 kg/m2 (as
defined in the general population) may not be optimal in
dialysis patients whether they are on or off the transplant list.20
The strengths of our study include the following: First, our
study is unique in that it used standardized anthropometric
measurements to quantify fat and muscle mass. Studies have
indicated that anthropometric measurements may be more
closely correlated with the gold standard of DEXA than
bioelectrical impedance in dialysis patients.21–23 We acknowl-
edge, however, that all measures of body composition,
particularly those related to fat free mass, may be affected
by hydration status.24 Second, we had a large sample with
detailed ascertainment of exposures, covariates, and out-
comes. Third, our results are for the most part generalizable
to maintenance HD patients since our mean (s.d.) of BMI
(25.2 (5.1)) is comparable to that in the United States Renal
Data System (USRDS), which has a mean (s.d.) BMI of
24.4 (5.3).25
Potential limitations of this study include first the fact that
the skin-fold measurements in this study quantified periph-
eral rather than central fat tissue. Central fat, however, is
thought to be a stronger risk factor for cardiovascular disease
both in the general population26 and in patients during all
stages of chronic kidney disease,27,28 and data from both
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human and animal studies suggest that there may be fat
redistribution in kidney disease.29,30 Second, the formulae
used for calculation of percent fat mass and muscle mass31,32
have not been validated for HD patients; therefore, we were
unable to provide the percent of body fat mass and muscle
mass in this study. Third, as in any observational study we
cannot account for unmeasured or residual confounding.
Fourth, the HEMO study excluded morbidly obese subjects
with weight over 100 kg.
Conclusion
Both low muscle and low peripheral fat mass are associated
with higher all-cause mortality in HD patients. These
findings need to be reproduced in additional studies and
may have important clinical implications regarding weight
loss recommendations in dialysis patients on and off the
transplant list.
MATERIALS AND METHODS
Study population
The HEMO study was a multi-center, randomized controlled,
clinical trial with a 2 2 factorial design, comparing high dialysis
dose (eKt/V 1.45) to standard dialysis dose (eKt/V 1.05), and
membrane flux of low (mean b2-microglobulin clearance o10 ml/
min) to high (mean b2-microglobulin clearance 420 ml/min and
ultrafiltration coefficient 414 ml/h/mm Hg). The patients were aged
18 to 80 years old, undergoing in-center HD three times weekly, and
had been on dialysis for at least 3 months. The exclusion criteria
included unstable angina and New York Heart Association Class IV
HF. The participants were evaluated during an 8- to 12-week
baseline period between March 1995 and October 2000. They were
excluded from randomization if they were unable to achieve a
dialysis dose of eKt/VX1.35 within 4.5 h, or if their residual kidney
urea clearance was 41.5 ml/min/35 l of urea distribution volume.
Patients with weight 4100 kg, severe malnutrition indicated by a
pre-dialysis albumin level of o2.8 g/dl, current malignances
requiring radiation or chemotherapy, symptomatic acquired im-
munodeficiency syndrome, cirrhosis with hepatic encephalopathy,
chronic pulmonary disease, and current hospitalization were also
excluded. A total of 1846 patients were enrolled in this study. All
patients received standard medical care for blood pressure control,
calcium–phosphorus balance, anemia, and other parameter control
by the Quality of Care Committee. Data collection ended in 31
December 2001. The range of follow-up period for individual
patients was 0.9–6.6 years, depending on the date of randomiza-
tion.33 Among the 1846 patients, 1709 had undergone measure-
ments of triceps skin-fold thickness, MAMC, and BMI.
Outcome variable
All-cause mortality was ascertained through contact with each
dialysis unit as well as through death certificates. Participants were
censored at the time of death, transplantation, or withdrawal from
the study or the study end date, 31 December 2001.
Body composition measurements
Certain anthropometric techniques assess body composition based
on a model in which the body consists of two chemically distinct
compartments: fat and fat-free mass. The fat-free mass consists of
the muscle mass, soft lean tissues, and the skeleton. Triceps skin-fold
thickness and MAMC are the most commonly used anthropometric
measurements in assessing these body compartments.
Anthropometric measurements34 were obtained by researchers
trained on standard techniques35 and were performed immediately
after a dialysis session during the baseline period. Triceps skin-fold
thickness and MAMC were obtained from the non-access side of the
body using 2–4 repeat measurements. Triceps skin-fold thickness
was used to assess fat mass. MAMC was used to assess muscle mass.
MAMC was calculated using the standard formula MAMC
(cm)¼Mid-upper arm circumferencep* Triceps skin-fold thick-
ness (cm).36 Height and post-dialysis (dry) weight were used to
calculate the BMI (weight in kg/(height in m)2).
Covariates
Age, sex, race, smoking history, and dialysis duration were obtained
through history. Race was classified as Black or non-Black. Diabetes
was defined based on current or past use of oral hypoglycemics.
Cerebral vascular disease, peripheral vascular disease, ischemic heart
disease, other heart disease, and HF were defined using the index of
Co-Existing Disease (ICED), a coding system that classifies the
presence and severity of different diseases.37–39 Pre-dialysis serum
albumin was determined monthly at the HEMO central laboratory.
Serum creatinine, calcium, and phosphorous levels were obtained
from local laboratory measurements.
Statistical analysis
Means and s.d.s were calculated for continuous variables, and
proportions were calculated for categorical variables. w2-Test or
analysis of variance was used to compare the proportion or means
among the different quartiles of triceps skin-fold thickness. The
Pearson correlations between triceps skin-fold thickness, MAMC,
and BMI were calculated.
The adjusted functional forms of triceps skin-fold thickness,
MAMC, and BMI, and their associations with all-cause mortality
were examined using restricted cubic splines and graphically
presented using the Design Library of the Statistical Software R.40,41
We used stratified Cox regression models allowing different
baseline hazard functions for the 15 Clinical Centers to evaluate the
risk factors for all-cause mortality. Univariate analysis was
performed to examine the relationship between each of the body
composition variables and all-cause mortality. Body composition
variables were initially evaluated as continuous variables per 1 s.d.
increase so as to enable comparisons between them, and
subsequently in quartiles.
In the multivariable models age, sex, race, and randomization
status were included in all models and other variables were added if
Po0.05 in stepwise selection. The interaction of baseline albumin
with follow-up time was included in the models to account for a
decline in the association of baseline albumin with all-cause
mortality over time. Other variables did not violate the proportional
hazards assumption.
Finally, interactions were performed between MAMC and triceps
skin-fold thickness, as well as each of the body composition
measures with sex, race, diabetes, ischemic heart disease, HF, other
heart disease, and smoking.
Sensitivity analyses
First, we included triceps skin-fold thickness and MAMC in the
same model so as to evaluate whether they confounded the
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importance of each other. Second, we adjusted for height because
BMI adjusts for height. Third, we excluded serum creatinine from
the multivariable models because of potential colinearity between
triceps skin-fold thickness, MAMC, and serum creatinine. Fourth,
we excluded patients who died within the first year so as to evaluate
whether the relationships are consistent over time.
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